B-type natriuretic peptide (BNP) is a cardiac-derived vasodilator and a biomarker for heart failure
elevated BNP and its cleavage product N-terminal proBNP (NT-proBNP) also predict adverse outcomes in acute coronary syndromes and other cardiovascular diseases1)
Potential pro-thrombotic activity
BNP can bind to natriuretic peptide receptor-A (NPRA) on platelets significantly increasing intracellular cGMP levels and enhanced platelet aggregation, granule secretion, spreading, and clot retraction in vitro2)